Cover Image

Neoadjuvant targeted therapy for resectable EGFR-mutant non-small cell lung cancer: Current status and future considerations

Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) targeted therapy has become the standard of care for patients with EGFR-mutated metastatic non-small cell lung cancer (NSCLC) on the basis of improved prognosis and reduced toxicities compared with chemotherapy. In view of the...

Full description

Saved in:

Bibliographic Details
Main Authors:	Wenliang Liu (Author), Siying Ren (Author), Ying Xiao (Author), Lulu Yang (Author), Chao Zeng (Author), Yan Hu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-11-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Osimertinib as Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer: A Case Series
by: Yan Hu, et al.
Published: (2022)

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
by: Yan Hu, et al.
Published: (2022)

Specific TCR profiles predict clinical outcome of adjuvant EGFR-TKIs for resected EGFR-mutant non-small cell lung cancer
by: Si-Yang Maggie Liu, et al.
Published: (2023)

Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
by: Jianghua Ding, et al.
Published: (2024)

Emerging precision neoadjuvant systemic therapy for patients with resectable non-small cell lung cancer: current status and perspectives
by: Luis A. Godoy, et al.
Published: (2023)

Role of Neoadjuvant Immune Checkpoint Inhibitors in Resectable Non-Small Cell Lung Cancer
by: Ivy Riano, et al.
Published: (2023)

Evidence for the evolving role of neoadjuvant and perioperative immunotherapy in resectable non-small cell lung cancer
by: Thomas Hansen, et al.
Published: (2024)

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
by: Zhe Zhang, et al.
Published: (2019)

Longitudinal nonlinear mixed effects modeling of EGFR mutations in ctDNA as predictor of disease progression in treatment of EGFR‐mutant non‐small cell lung cancer
by: Julie M. Janssen, et al.
Published: (2022)

Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery
by: Hyein Jeon, et al.
Published: (2024)

Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States
by: Gengwei Huo, et al.
Published: (2024)

Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer
by: Pacini L, et al.
Published: (2021)

Targeting <i>BRAF</i> Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in <i>EGFR</i>-Mutant Non-Small-Cell Lung Cancer
by: Frank Aboubakar Nana, et al.
Published: (2021)

EGFR Inhibitors for Neoadjuvant and Adjuvant Therapy of NSCLC
by: Fabio Villa
Published: (2015)

Predictive value of intra‐tumoural TCRβ rearrangements in precisely selecting adjuvant therapy for EGFR‐mutant non‐small‐cell lung cancer
by: Cunte Chen #, et al.
Published: (2022)

BMP4 Upregulation Is Associated with Acquired Drug Resistance and Fatty Acid Metabolism in EGFR-Mutant Non-Small-Cell Lung Cancer Cells
by: Duc-Hiep Bach, et al.
Published: (2018)

Elevated murine HB-EGF confers sensitivity to diphtheria toxin in EGFR-mutant lung adenocarcinoma
by: Camila Robles-Oteiza, et al.
Published: (2021)

Targeting Mutant Kirsten Rat Sarcoma Viral Oncogene Homolog in Non-Small Cell Lung Cancer: Current Difficulties, Integrative Treatments and Future Perspectives
by: Jia-Xin Li, et al.
Published: (2022)

Naples Prognostic Score as an Independent Predictor of Survival Outcomes for Resected Locally Advanced Non-Small Cell Lung Cancer Patients After Neoadjuvant Treatment
by: Zou Z, et al.
Published: (2023)

β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer
by: Cong Xu, et al.
Published: (2023)

AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer
by: Geunho Choi, et al.
Published: (2021)

The Multi-Omics Analysis of Key Genes Regulating EGFR-TKI Resistance, Immune Infiltration, SCLC Transformation in EGFR-Mutant NSCLC
by: Wang Z, et al.
Published: (2022)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
by: Jiabao Hou, et al.
Published: (2022)

Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
by: Jingjing Shi, et al.
Published: (2023)

Structure-activity exploration of a small-molecule allosteric inhibitor of T790M/L858R double mutant EGFR
by: Francesca Foschi, et al.
Published: (2023)

EGFR mutation testing in non-small cell lung cancer (NSCLC)
by: Fouad Al Dayel
Published: (2012)

A case of Ph+ acute lymphoblastic leukemia and EGFR mutant lung adenocarcinoma synchronous overlap: may one TKI drug solve two diseases?
by: Qi Zhang, et al.
Published: (2024)

Iterative surgical resections in non-small cell lung cancer
by: Ahmet Ucvet, et al.
Published: (2022)

Clinical and surgical implications of EGFR mutations in non-small cell lung cancer
by: M. Yoon, et al.
Published: (2016)

Non-small-cell lung cancer: how to manage EGFR-mutated disease
by: Federica Pecci, et al.
Published: (2022)

EGFR-gene analysis on cytological specimens of non-small-cell lung cancers
by: Feichter G, et al.
Published: (2007)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
by: Xiaoyu Qian, et al.
Published: (2022)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
by: Jiaxin Zhang, et al.
Published: (2022)

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer
by: Jonathan R. Thompson, et al.
Published: (2016)

EGFR mutations as a prognostic and predictive marker in non-small-cell lung cancer
by: Fang S, et al.
Published: (2014)

MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
by: Chao-Ju Chen, et al.
Published: (2021)

Pan-Immune-Inflammatory Value in Patients with Non-Small-Cell Lung Cancer Undergoing Neoadjuvant Immunochemotherapy
by: Zhai WY, et al.
Published: (2023)

Current status of immunotherapy for non-small cell lung cancer
by: Tao Yang, et al.
Published: (2022)

Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis
by: Zhaolun Cai, et al.
Published: (2018)

Current status and future perspectives of liquid biopsy in non-small cell lung cancer
by: Sunhee Chang, et al.
Published: (2020)